Dr Matt O'Shea MBChB, MRCP, FRCPath, DPhil (Oxon), DTM&H

Matt O'Shea

Institute of Immunology and Immunotherapy
Associate Clinical Professor
Consultant in Infectious Diseases and Clinical Microbiology
Surgeon Commander, Royal Navy

Contact details

Institute of Immunology and Immunotherapy
College of Medical and Dental Sciences
University of Birmingham
B15 2TT

Dr Matt O’Shea is a military clinical academic based in the College of Medical and Dental Sciences’ Institute of Immunology and Immunotherapy. He divides his time between providing clinical care and leading a programme of infection research. He is interested in a wide range of clinically important infections, their diagnosis, treatment, and prevention, and in particular the interaction between the human host and pathogens. His research primarily focuses on understanding human immune responses to Mycobacterium tuberculosis and using this knowledge translationally to improve patient care by developing novel diagnostics, treatments and to identify vaccine candidates. As a consultant physician in Infectious Diseases and Clinical Microbiology, he cares for patients at hospitals in the University Hospitals Birmingham NHS Foundation Trust.


  • Certificate of Completion of Training (CCT) in Infectious Diseases and Clinical Microbiology, 2019
  • Fellow of the Royal College of Pathologists (FRCPath), 2019
  • Doctor of Philosophy (DPhil), University of Oxford, 2016
  • Diploma in Tropical Medicine and Hygiene (DTM&H) (Distinction), Liverpool School of Tropical Medicine & Hygiene, 2010
  • Member of the Royal College of Physicians (MRCP), 2009
  • Bachelor of Medicine and Bachelor of Surgery (MBChB), University of Birmingham, 2003
  • Master of Philosophy (MPhil) in Infection, University of Birmingham & Naval Health Research Center San Diego, 2002
  • Bachelor of Science (BSc) in Medical Biochemistry (First Class Hons), University of Birmingham, 1996


Dr O’Shea received his BSc in Biochemistry from the University of Birmingham in 1996 and then went on to study Medicine there (1997-2003). Interested in academic medicine and, in particular, infectious diseases and tropical medicine from an early stage, he undertook an MPhil by research in Infection at the Naval Health Research Center in San Diego, USA (2000-2001).

After qualifying in Medicine (MBChB, 2003) he undertook clinical rotations in Birmingham and Worcester. In 2009 he completed MRCP and subsequently started specialty clinical training in Infectious Diseases in the West Midlands Deanery (Heartlands Hospital). Dr O’Shea completed the DTM&H at the Liverpool School of Tropical Medicine and Hygiene (2010) and has undertaken clinical work in resource-poor settings (Malawi, Afghanistan and Sierra Leone).

Having been awarded a Wellcome Trust Research Training Fellowship and Senior Scholarship (Corpus Christi College, Oxford) he completed his DPhil at the Jenner Institute (University of Oxford) in 2016 on Tuberculosis (TB) immunology (The characterisation of mycobacterial control profiles and underlying immune signatures in patients with latent tuberculosis infection and active disease).

Dr O’Shea then returned to Birmingham to complete clinical training and to take up an Honorary Clinical Lectureship in the IMI. He was subsequently promoted to Honorary Senior Clinical Research Fellow in the III. During this time he established a research group with a portfolio of clinically relevant, infection-related research, primarily focussed on TB. Dr O’Shea was elected FRCPath in 2019 and dual accredited as a Consultant in Infectious Diseases and Clinical Microbiology thereafter. He was appointed as substantive Associate Clinical Professor in Infection in 2023.

In addition, Dr O’Shea is a military clinician (Royal Navy and Defence Medical Services) and has deployed extensively since commissioning in 1999. He is the Defence Consultant Adviser in Pathology, Senior Lecturer in Defence Pathology and a member of the Academic Department of Military Medicine at the Royal Centre for Defence Medicine, Birmingham. His military research is focussed on improving the diagnosis and treatment of infections in operational settings and the firm-base.


Dr O’Shea teaches on the MBChB, BMedSc and Postgraduate courses on various aspects of infection diseases and microbiology. He also delivers clinical bedside teaching to medical students and junior doctors on the wards.

Postgraduate supervision

Dr O’Shea supervises Doctoral students in clinically-relevant, infection-related research, primarily focussed on the human host immune response to mycobacteria (M.tuberculosis), vaccine development and novel TB diagnostics and therapeutic approaches.

If you are interesting in studying any of these subject areas please contact Dr Matt O'Shea directly, or
for any general doctoral research enquiries, please email mds-gradschool@contacts.bham.ac.uk

For a full list of available Doctoral Research opportunities, please visit our Doctoral Research programme listings  

Current members

Dr Erin Aldera – Post-Doctoral Scientist

Erin pursued both her undergraduate and postgraduate studies at the University of Cape Town, graduating with a BSc specialising in Physiology and Microbiology in 2011, BSc (Med)(Hons) in 2012 and PhD in 2018. For her doctoral studies she investigated early-life immunity and the susceptibility of children to mycobacteria by relating vaccine- and helminth-specific antibody responses to their mycobacterial infection outcome. Erin joined the O’Shea group in early 2019 as a Newton International Fellow. Erin is examining the role that helminth-induced eosinophils play in the host immune response to mycobacterial infection by exploring whether these innate cells (classically linked to helminth infection control) can inhibit mycobacterial growth and the mechanisms used.

Charlotte Jones – Senior Laboratory Technician

Charlotte joined the O'Shea group in August 2016, after working for Professor Adam Cunningham on immune responses to Salmonella Typhimurium. Charlotte's background is in microbiology after graduating from the University of Birmingham in Cell and Molecular Biology (BMedSci, 2010). As she has always enjoyed studying, Charlotte undertook a Masters of Biomedical Science by flexible learning with Nottingham Trent University in 2015, graduating in 2017. Since her graduate degree, she has developed an interest in Mycobacterium tuberculosis, particularly the immunological relationship between latent infection and active disease. Charlotte was thrilled to take her current position to study this area using clinical samples and a variety of laboratory techniques (e.g. ELISAs, ELISpot/FluoroSpot, flow cytometry and BACTEC MGIT system).

Dr Danai Papakonstantinou – PhD Student

Danai graduated from the Medical School of the University of Athens (Greece) with an MD in 2005 and went on to complete a Master’s Degree and the Diploma in Tropical Medicine (DTM&H) at the London School of Hygiene and Tropical Medicine (2008-2009). Danai has worked as a medical doctor in Greece and the UK for more than 10 years and specialises in Infectious Diseases and General Internal Medicine in the West Midlands. Danai holds an honorary contract with Heartlands Hospital (Birmingham) as a Senior Registrar in Infectious Diseases and holds a specialty certificate in Infectious Diseases (British Infection Association and Royal College of Physicians). Danai is currently a PhD student in the O’Shea group (co-supervisors Professor Alan McNally and Professor Adam Cunningham) and holds a Global Challenges Scholarship (University of Birmingham). Danai is using bioinformatics to study the Mycobacterium tuberculosis genome to identify novel TB vaccine candidates and antigens for TB diagnostics.

Dr Gabby Morley – PhD Student

Gabby graduated from the University of Birmingham in 2015 with Honours in Medicine and Surgery (MBChB Hons). Through her work as a medical doctor, she developed a keen interest in infectious diseases, however seeing first-hand how certain infections were becoming more challenging to treat due to the rise of antimicrobial resistance. This interest led Gabby to apply for the Wellcome Trust Antimicrobial and Antimicrobial Resistance Doctoral Training Programme and start work in Dr Matt O’Shea’s group, at the University of Birmingham, investigating human immune responses to Mycobacterium tuberculosis (M.tb; co-supervisor Professor Adam Cunningham). Gabby's work aims to increase understanding of the human-M.tb interaction, with particular emphasis on the humoral response to M.tb, to facilitate novel management strategies for tackling drug-resistant M.tb.

Recent past members

Roxanne Pillay – Visiting Research Student

Roxanne is a registered Medical Technologist with the Health Professions Council of South Africa (HPCSA), specialising in Clinical Pathology and Chemical Pathology. She obtained a National Diploma (Biomedical Technology) and Bachelor of Technology (Biomedical Technology) from Durban University of Technology, South Africa, in 2006 and 2012 (respectively). She has since worked as a medical technologist in various pathology laboratories in South Africa. Roxanne has extensive experience in diagnostic testing in clinical pathology and also in implementation and maintenance of quality assurance systems for medical laboratories (ISO15189) and laboratory management. Her academic career began in 2017 when she joined the Mangosuthu University of Technology, South Africa as an NGAP lecturer. She was, until recently, a visiting research student at University of Birmingham (Dr Matt O’Shea’s lab) and is participating in an ongoing collaboration between South Africa and Birmingham as part of her Masters and PhD studies. Roxanne's research focuses on the direct interactions between helminths and bacteria with the aim of identifying novel antimicrobial agents.



Tuberculosis, helminths, B cells, antibodies, T cells, generation and maintenance of adaptive responses, vaccination, immune homeostasis, immune modulation.

Lay summary

Our work aims to understand how the human immune system responds to infection with Mycobacterium tuberculosis. We also study how other pathogens influence this immune response and whether they have an enhancing or diminishing effect. By increasing our knowledge of these processes, we can generate new vaccines and treatments to tackle the huge burden of TB.


Mycobacterium tuberculosis (M.tb), the bacterial pathogen which causes tuberculosis (TB), is an ancient disease and the leading cause of death from a single infectious agent globally.  The World Health Organisation estimates that TB accounts for over 10 million new infections and 1.3 million deaths per year. The staggering scale of the TB disease burden is compounded by HIV co-infection and the emergence of multi-, extensively- and now totally-drug resistant strains of M.tb. Furthermore, modelling suggests that almost 25% of the world’s population has latent (dormant) infection, representing a huge reservoir of potential new disease and thus infectiousness.

However, infections rarely occur in isolation and there is significant overlap between M.tb and other endemic diseases in certain regions of the world. For example, one third of the world’s population is thought to be infected with soil-transmitted helminths and the helminth-M.tb co-infection rate is estimated at 20-35% in some low-middle income countries. This highlights that the geographical overlap of these pathogens is not inconsequential and frequently effects very vulnerable individuals. Our current knowledge about how helminths might influence M.tb infection is limited.

It is widely acknowledged that improved diagnostic tests, novel antibiotics and therapeutics are required to tackle the global TB epidemic. While stopping TB transmission with effective anti-tuberculous treatment is one of the cornerstones of TB control programmes, the discovery of a new globally effective TB vaccine remains the most cost effective, long-term control strategy.

Improved understanding of human-M.tb interactions, and the influence of co-infections, will provide opportunities to exploit the immune response to M.tb and therefore has potential translational clinical application through the development of novel diagnostics and therapeutics.

Our research uses clinical samples, in vivo and ex vivo models of infection and a variety of techniques to study immune responses to mycobacteria. While our particular focus is on adaptive immunity, we are also engaged in studying the contribution of innate responses in the control of M.tb.

Some examples of current research themes in the O’Shea laboratory include:

  1. How B cell and antibody responses to mycobacterial antigens develop and assessing their role in the control and pathogenesis of M.tb infection.
  2. Characterisation of antibody response profiles to proteinaceous and non-proteinaceous M.tb antigens in clinical samples from patients with different forms of TB infection and disease at baseline and in response to therapy.
  3. Generating monoclonal antibodies directed against mycobacterial antigens to study their role in modulating responses to M.tb and their application in novel diagnostics and therapeutics.
  4. Using computational biology and bioinformatics to identify sub-dominant M.tb antigens as a novel approach to find targets for candidate vaccine development.
  5. Understanding the human host immune response across the spectrum of latent infection and TB disease and its relationship to mycobacterial control and pathogenesis.
  6. How gastrointestinal helminth infections affect host homeostasis, immune function and the modulation of responses to mycobacteria.
  7. Whether helminth-activated eosinophils have an anti-mycobacterial role in the control of M.tb infection.

Our work has shown that patients with active disease have the greatest control of mycobacterial growth in a whole blood mycobacterial growth inhibition assay, whilst there is a continuum of responses among latently infected patients, likely related to the degree of immune activation in response to bacillary load. The improved control we have observed is correlated with multiple factors including inflammatory monocytes, activated and atypical memory B cells, IgG1 responses to M.tb-specific antigens and serum cytokines/chemokines. Our findings are important as they offer a method to stratify subclinical TB infections and the future potential to identify individuals most at risk of progressing to active disease. In addition, we have identified a significant negative association between gastrointestinal hookworm and latent TB infections. Blood from individuals with hookworm have a greater ability to control virulent mycobacterial growth in vitro than from those without, which is lost following hookworm treatment. An eosinophil-associated differential gene expressioncharacterises the whole blood transcriptome of hookworm infection and correlates with improved mycobacterial control. These data suggest a possible anti-mycobacterial role for helminth-induced eosinophils which are investigating further.

Other activities

Dr O’Shea’s other activities include:

  • Reviewer for a number of internationally-competitive journals and funding agencies in the UK and abroad
  • Member of the IMI Management Board
  • Examiner for PhD and MD candidates in UK and overseas
  • Member of the Military Infection Working Group

Professional memberships include:

  • Royal College of Physicians
  • Royal College of Pathologists
  • Royal Society of Medicine
  • British Infection Association
  • British Society of Immunology
  • Hospital Infection Society
  • The Acid Fast Club


A full list of publications can be found here.

Chetty A, Darby MG, Pillaye J, Taliep A, Cunningham AF, O'Shea MK, Katawa G, Layland LE, Ritter M, and Horsnell WGC (2023) Induction of Siglec-FhiCD101hi eosinophils in the lungs following murine hookworm Nippostrongylus brasiliensis infection. Front Immunol. 14:1170807. doi: 10.3389/fimmu.2023.1170807. PMID: 37251384.

Ferentinos P, Snape D, Koivula F, Faustini S, Nicholson-Little A, Stacey M, Gifford R, Parsons I, Lamb L, Greeves J, O'Hara J, Cunningham AF, Woods D, Richter A, and O'Shea MK (2023) Validation of dried blood spot sampling for detecting SARS-CoV-2 antibodies and total immunoglobulins in a large cohort of asymptomatic young adultsJ Immunol Methods. 518:113492. doi: 10.1016/j.jim.2023.113492. PMID: 37201783.

Pallett SJC, Heskin J, Keating F, Mazzella A, O'Shea MK, and Moore LSP (2023) Risk of omicron infection for high-risk older adults in long-term care facilities. Lancet Infect Dis. 23(5):526-527. doi: 10.1016/S1473-3099(23)00179-2. PMID: 36940702.

Clarke J, Moore M, O'Shea MK, and Dedicoat M (2023) Identifying opportunities to improve the microbiological diagnosis of tuberculosis in a low endemic urban setting. J Infect. S0163-4453(23)00137-8. doi: 10.1016/j.jinf.2023.03.008. PMID: 36906151.

Bosworth A, Robson J, Lawrence B, Casey AL, Fair A, Khanam S, Hudson C, and O'Shea MK (2023) Deployment of whole genome next-generation sequencing of SARS-CoV-2 in a military maritime settingBMJ Mil Health. e002296. doi: 10.1136/military-2022-002296. PMID: 36759003.

Woolley SD, Chambers R, Bishop JRB, Logan A, McMillan P, Fletcher TE, Taegtmeyer M, and O'Shea MK (2023) COVID-19 risk, attitudes and behaviour study (CRAB study): A knowledge, attitudes, and practise qualitative study of COVID-19 in the Royal Navy. Front. Public Health. 10:1101817. doi: 10.3389/fpubh.2022.1101817. PMID: 36711341.

Woolley SD, Dermont M, Adam M, Pallet SJC, Reece N, Hoysal N, Holden G, Attridge KK, Fletcher TE, O'Shea MK, Hutley EJ, Nicol ED, and Lamb LE (2022) The 2022 monkeypox outbreak: A UK military perspective. Travel Med Infect Dis. 52:102540. doi: 10.1016/j.tmaid.2022.102540. PMID: 36587754.

O'Shea M, Birkhamshaw E, Khalil R, Wickramasinghe N, Hamad M, Crooks N, and Winzor G (2022) Implementation of a diagnostic algorithm for COVID-19-associated pulmonary aspergillosis. J Hosp Infect. 129:203-206. doi: 10.1016/j.jhin.2022.07.023. PMID: 35940289.

Pallett SJ, Jones R, Abdulaal A, Pallett MA, Rayment M, Patel A, Denny SJ, Mughal N, Khan M, Rosadas de Oliveira C, Pantelidis P, Randell P, Toumazou C, O'Shea MK, Tedder R, McClure MO, Davies GW, and Moore LS (2022) Variability in detection of SARS-CoV-2-specific antibody responses following mild infection: a prospective multicentre cross-sectional study, London, United Kingdom, 17 April to 17 July 2020Euro Surveill. 27(4):2002076. doi: 10.2807/1560-7917.ES.2022.27.4.2002076. PMID: 35086612. 

Bitencourt J, Peralta-Álvarez MP, Wilkie M, Jacobs A, Wright D, Salman Almujri S, Li S, Harris SA, Smith SG, Elias SC, White AD, Satti I, Sharpe SS, O'Shea MK, McShane H, Tanner R (2022) Induction of Functional Specific Antibodies, IgG-Secreting Plasmablasts and Memory B Cells Following BCG Vaccination. Front Immunol. 12:798207. doi: 10.3389/fimmu.2021.798207. PMID: 35069580. 

Llibre A, Dedicoat M, Burel JG, Demangel C, O'Shea MK, and Mauro C (2021) Host Immune-Metabolic Adaptations Upon Mycobacterial Infections and Associated Co-Morbidities. Front Immunol. 12:747387. doi: 10.3389/fimmu.2021.747387. PMID: 34630426.

Burel JG, Singhania A, Dubelko P, Muller J, Tanner R, Parizotto E, Dedicoat M, Fletcher TE, Dunbar J, Cunningham AF, Lindestam Arlehamn CS, Catanzaro DG, Catanzaro A, Rodwell T, McShane H, O'Shea MK, and Peters B (2021) Distinct blood transcriptomic signature of treatment in latent tuberculosis infected individuals at risk of developing active diseaseTuberculosis (Edinb). 131:102127. doi: 10.1016/j.tube.2021.102127. PMID: 34555657.

Llibre A, Grudzinska FS, O'Shea MK, Duffy D, Thickett DR, Mauro C, Scott A (2021) Lactate cross-talk in host-pathogen interactions. Biochem J. 478(17), 3157-3178. doi: 10.1042/BCJ20210263.PMID: 34492096. 

Tanner R, Hoogkamer E, Bitencourt J, White A, Boot C, Sombroek CC, Harris SA, O'Shea MK, Wright D, Wittenberg R, Sarfas C, Satti I, Verreck FAW, Sharpe SA, Fletcher HA, and McShane H (2021) The in vitro direct mycobacterial growth inhibition assay (MGIA) for the early evaluation of TB vaccine candidates and assessment of protective immunity: a protocol for non-human primate cells. F1000Res. 10:257. doi: 10.12688/f1000research.51640.1. PMID: 33976866. 

Faustini SE, Jossi SE, Perez-Toledo M, Shields AM, Allen JD, Watanabe Y, Newby ML, Cook A, Willcox CR, Salim M, Goodall M, Heaney JL, Marcial-Juarez E, Morley GL, Torlinska B, Wraith DC, Veenith TV, Harding S, Jolles S, Ponsford MJ, Plant T, Huissoon A, O'Shea MK, Willcox BE, Drayson MT, Crispin M, Cunningham AF, and Richter AG (2021) Development of a high-sensitivity ELISA detecting IgG, IgA and IgM antibodies to the SARS-CoV-2 spike glycoprotein in serum and saliva. Immunology, 164(1). doi: 10.1111/imm.13349. PMID: 33932228. 

Chetty A, Darby MG, Vornewald PM, Martín-Alonso M, Filz A, Ritter M, McSorley HJ, Masson L, Smith K, Brombacher F, O'Shea MK, Cunningham AF, Ryffel B, Oudhoff MJ, Dewals BG, Layland LE, and Horsnell WGC (2021) Il4ra-independent vaginal eosinophil accumulation following helminth infection exacerbates epithelial ulcerative pathology of HSV-2 infection. Cell Host Microbe, 29(4):579-593.e5. doi:10.1016/j.chom.2021.02.004. PMID: 33857419. 

Wall N, Godlee A, Geh D, Jones C, Faustini S, Harvey R, Penn R, Chanouzas D, Nightingale P, O'Shea M, Richter A, Moss P, Cunningham A, and Harper L (2021) Latent Cytomegalovirus Infection and Previous Capsular Polysaccharide Vaccination Predict Poor Vaccine Responses in Older Adults, Independent of Chronic Kidney DiseaseClin Infect Dis. 17:ciab078. doi: 10.1093/cid/ciab078. PMID: 33728434.

Papakonstantinou D, Dunn SJ, Draper SJ, Cunningham AF, O'Shea MK, McNally A. (2021) Mapping Gene-by-Gene Single-Nucleotide Variation in 8,535 Mycobacterium tuberculosis Genomes: a Resource To Support Potential Vaccine and Drug Development. mSphere, 10;6(2):e01224-20. doi: 10.1128/mSphere.01224-20. PMID: 35940289. 

Riste M, Davda P, Smith EG, Wyllie DH, Dedicoat M, Jog S, Laird S, Langman G, Jenkins N, Stevenson J, O'Shea MK (2021) Prosthetic hip joint infection by Bacillus Calmette-Guerin therapy following intravesical instillation for bladder cancer identified using whole-genome sequencing: a case report. BMC Infect Dis. 21(1):151. doi: 10.1186/s12879-021-05831-3. PMID: 33546627.

Parsons IT, Gifford RM, Stacey MJ, Lamb LE, O'Shea MK, Woods DR (2021) Does vitamin D supplementation prevent SARS-CoV-2 infection in military personnel? Review of the evidenceBMJ Mil Health. doi: 10.1136/bmjmilitary-2020-001686. Online ahead of print. PMID: 33504571. 

Tanner R, White AD, Boot C, Sombroek CC, O'Shea MK, Wright D, Hoogkamer E, Bitencourt J, Harris SA, Sarfas C, Wittenberg R, Satti I, Fletcher HA, Verreck FAW, Sharpe SA, and McShane H (2021) A non-human primate in vitro functional assay for the early evaluation of TB vaccine candidatesNPJ Vaccines. 4;6(1):3. doi: 10.1038/s41541-020-00263-7. PMID: 33397986.

McMaster D, Courtenay M, Santucci C, Davies AP, Kirby A, Seddon O, Price DA, Barlow G, Lim FH, Davies BS, O'Shea MK, Collini P, Basarab M, Ahmad A, Albur M, Hemsley C, Brown NM, O'Gorman C, Rautemaa-Richardson R, Davies GR, Penfold CN, Patel S; Keep Antibiotics Working (KAW) group (2020) Consensus-based antimicrobial resistance and stewardship competencies for UK undergraduate medical studentsJAC Antimicrob Resist. 4;2(4):dlaa096. doi: 10.1093/jacamr/dlaa096. PMID: 34223048.

Morley GL, Taylor S, Jossi S, Perez-Toledo M, Faustini SE, Marcial-Juarez E, Shields AM, Goodall M, Allen JD, Watanabe Y, Newby ML, Crispin M, Drayson MT, Cunningham AF, Richter AG, and O'Shea MK (2020) Sensitive Detection of SARS-CoV-2-Specific Antibodies in Dried Blood Spot Samples. Emerg Infect Dis. 26(12):2970-2973. doi: 10.3201/eid2612.203309. PMID: 32969788. 

Canning B, Mohamed I, Wickramasinghe N, Swindells J, and O'Shea MK (2020) Thermonuclease test accuracy is preserved in methicillin-resistant Staphylococcus aureus isolates. J Med Microbiol. 69(4):548-551. doi: 10.1099/jmm.0.001166. PMID: 32101159.

Tanner R, Satti I, Harris SA, O'Shea MK, Cizmeci D, O'Connor D, Chomka A, Matsumiya M, Wittenberg R, Minassian AM, Meyer J, Fletcher HA, and McShane H (2020) Tools for Assessing the Protective Efficacy of TB Vaccines in Humans: in vitro Mycobacterial Growth Inhibition Predicts Outcome of in vivo Mycobacterial Infection. Front Immunol. 10;10:2983. doi: 10.3389/fimmu.2019.02983. PMID: 31998295.

Wilkie M, Satti I, Minhinnick A, Harris S, Riste M, Ramon RL, Sheehan S, Thomas ZM, Wright D, Stockdale L, Hamidi A, O'Shea MK, Dwivedi K, Behrens HM, Davenne T, Morton J, Vermaak S, Lawrie A, Moss P and McShane H (2019) A phase I trial evaluating the safety and immunogenicity of a candidate tuberculosis vaccination regimen, ChAdOx1 85A prime - MVA85A boost in healthy UK adults. Vaccine pii: S0264-410X(19)31504-X

Müller J, Tanner R, Matsumiya M, Snowden MA, Landry B, Satti I, Harris SA, O'Shea MK, Stockdale L, Marsay L, Chomka A, Harrington-Kandt R, Manjaly Thomas ZR, Stylianou E, Naranbhai V, Mbandi SK, Hatherill M, Hussey G, Mahomed H, Tameris M, McClain JB, Hanekom WA, Evans TG, Scriba TJ, McShane H and Fletcher HA (2019) Cytomegalovirus infection is a risk factor for TB disease in Infants. JCI Insight pii: 130090

Jauneikaite E, Ferguson T, Mosavie M, Fallowfield JL, Davey T, Thorpe N, Allsopp A, Shaw AM, Fudge D, O'Shea MK, Wilson D, Morgan M, Pichon B, Kearns AM, Sriskandan S and Lamb LE (2019) Staphylococcus aureus colonization and acquisition of skin and soft tissue infection among Royal Marines recruits: a prospective cohort study. Clin Microbiol Infect pii: S1198-743X(19)30403-3

Fletcher TE, Leblebicioglu H, Bozkurt I, Sunbul M, Bilek H, Asik Z, Barut S, Gunes F, Gemici U, Hewson R, Wilson D, O'Shea MK, Woolley T, Faragher B, Parmar K, Lalloo DG, Beeching NJ and Hunt BJ (2019) Rotational thromboelastometry alongside conventional coagulation testing in patients with Crimean-Congo haemorrhagic fever: an observational cohort study. Lancet Infect Dis 19(8):862-871

O'Shea MK, Fletcher TE, Muller J, Tanner R, Matsumiya M, Bailey JW, Jones J, Smith SG, Koh G, Horsnell WG, Beeching NJ, Dunbar J, Wilson D, Cunningham AF and McShane H (2018) Human Hookworm Infection Enhances Mycobacterial Growth Inhibition and Associates With Reduced Risk of Tuberculosis Infection. Front Immunol 9:2893

McNeill E, Stylianou E, Crabtree MJ, Harrington-Kandt R, Kolb AL, Diotallevi M, Hale AB, Bettencourt P, Tanner R, O'Shea MK, Matsumiya M, Lockstone H, Müller J, Fletcher HA, Greaves DR, McShane H and Channon KM (2018) Regulation of mycobacterial infection by macrophage Gch1 and tetrahydrobiopterin. Nat Commun 9(1):5409

O'Shea MK, Tanner R, Müller J, Harris SA, Wright D, Stockdale L, Stylianou E, Satti I, Smith SG, Dunbar J, Fletcher TE, Dedicoat M, Cunningham AF and McShane H (2018) Immunological correlates of mycobacterial growth inhibition describe a spectrum of tuberculosis infection. Sci Rep 8(1):14480

Harris SA, White A, Stockdale L, Tanner R, Sibley L, Sarfas C, Meyer J, Peter J, O'Shea MK, Manjaly Thomas ZR, Hamidi A, Satti I, Dennis MJ, McShane H and Sharpe S (2018). Development of a non-human primate BCG infection model for the evaluation of candidate tuberculosis vaccines. Tuberculosis 108:99-105

Dickson SJ, Clay KA, Adam M, Ardley C, Bailey MS, Burns DS, Cox AT, Craig DG, Espina M, Ewington I, Fitchett G, Grindrod J, Hinsley DE, Horne S, Hutley E, Johnston AM, Kao RLC, Lamb LE, Lewis S, Marion D, Moore AJ, Nicholson-Roberts TC, Phillips A, Praught J, Rees PS, Schoonbaert I, Trinick T, Wilson DR, Simpson AJ, Wang D, O'Shea MK and Fletcher TE (2018) Enhanced case management can be delivered for patients with EVD in Africa: Experience from a UK military Ebola treatment centre in Sierra Leone. J Infect 76(4):383-392

Tanner R, O'Shea MK, White AD, Müller J, Harrington-Kandt R, Matsumiya M, Dennis MJ, Parizotto EA, Harris S, Stylianou E, Naranbhai V, Bettencourt P, Drakesmith H, Sharpe S, Fletcher HA and McShane H (2017) The influence of haemoglobin and iron on in vitro mycobacterial growth inhibition assays. Sci Rep 3;7:43478

View all publications in research portal